MedTrace Logo

Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids

NCT01529281 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-02-08

No results posted yet for this study

Summary

It is well documented that exercise-induced muscle damage (EIMD) decreases muscle function and causes severe soreness and discomfort. Branched-chain amino acid (BCAA) supplementation has been shown to increase protein synthesis and decrease muscle protein breakdown, however, the effects of BCAAs on recovery from EIMD are unknown. Thus, the aim of this study was to examine the effects of a BCAA supplement on markers of muscle damage.

Conditions

  • Exercise-induced Muscle Damage

Interventions

DIETARY_SUPPLEMENT

Branch Chain Amino Acid (BCAA)

Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with \~300 ml of water.

DIETARY_SUPPLEMENT

Placebo - asparmate

Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with \~300 ml of water.

Sponsors & Collaborators

  • Northumbria University

    lead OTHER

Principal Investigators

  • Glyn Howatson, PhD · Northumbria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-09-30
Completion
2011-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01529281 on ClinicalTrials.gov